DIRS.INFO The most relevant business & tech news

☆ This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
▼ + stars: | 2024-01-29 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline. "We see BEAM outperforming our coverage over the mid-term, with current levels being an attractive entry point," the analyst said. The stock is down more than 4% so far this year, and has lost more than 42% over the past 12 months. BEAM 1Y mountain Beam stock. He added that BEAM-302 is "uniquely positioned" as a one-time genetic medicine for AATD, particularly given its success in preclinical trials.

Persons: Eric Joseph, Joseph Organizations: Beam Therapeutics, TAM Locations: U.S, 1H24

☆ Stocks making the biggest moves midday: Dollar Tree, iRobot, Bloom Energy and more
▼ + stars: | 2024-01-29 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Dollar Tree — Shares of the discount retail chain popped 1% following an upgrade to overweight from neutral at JPMorgan. SoFi Technologies — Shares of the financial services provider surged 21% after the company reported its fourth-quarter financial results. ZoomInfo Technologies — Shares jumped more than 6% after Bank of America upgraded shares to buy from neutral on revenue growth acceleration. The firm cited tailwinds including improving market share and volume trends, as well as an attractive valuation and strong top-line growth. Flywire — Shares of the fintech company gained 3.75% after being upgraded by Morgan Stanley to overweight from equal weight.

Persons: McGrath RentCorp, McGrath, SoFi, iRobot, Koji Ikeda, Wells, Flywire, Morgan Stanley, Beam, —, Samantha Subin, Yun Li, Michelle Fox, Alex Harring, Lisa Kailai Han, Sarah Min, Pia Singh, Tanaya Macheel Organizations: WillScot Mobile, JPMorgan, Wall, Amazon, Bain Capital, Western Digital, Kioxia Holdings, Bloom Energy, Bank of America, ZoomInfo, Hershey —, AllianceBernstein, Warner Bros, —, Beam Locations: Japan, AATD

☆ Stocks making the biggest moves premarket: Dollar Tree, American Airlines, ZoomInfo Technologies and more
▼ + stars: | 2024-01-29 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

American Airlines — The airline stock added 1.5% following an upgrade to buy from neutral at Citi. "North America's network carriers' diversified revenue streams and solid demand for premium cabin offerings appear to provide them with superior positioning in this post-pandemic environment," wrote analyst Stephen Trent. Builders FirstSource — The building materials manufacturer edged 2% higher following an upgrade to buy from neutral at Bank of America. ZoomInfo Technologies — The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. "We believe it is a classic self-help story that is set to outperform," the analyst wrote, underscoring the company's revenue growth reacceleration and new AI products as potential catalysts.

Persons: Stephen Trent, Flywire, Morgan Stanley, Omar Nokta, Hershey, Wells, Steven Cahall, —, Cowen, Rafe Jadrosich, Julien Dumoulin, Smith, FactSet, Koji Ikeda, McGrath RentCorp — McGrath RentCorp, CNBC's Michelle Fox, Alexander Harring, Sarah Min, Jesse Pound Organizations: JPMorgan, American Airlines —, Citi, Zim Integrated Shipping Services —, Jefferies, Warner Bros, Bank of America, Bloom Energy, Koninklijke Philips —, Food and Drug Administration, Technologies, WillScot Mobile Locations: Albemarle, Netherlands

☆ Here are Monday's biggest analyst calls: Nvidia, Netflix, Apple, Micron, Hershey, Dollar Tree, Qualcomm & more
▼ + stars: | 2024-01-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

JPMorgan upgrades Dollar Tree to overweight from neutral JPMorgan said in its upgrade of the stock that it's a "self-help" story. Bernstein upgrades Hershey to outperform from market perform Bernstein said in its upgrade of the chocolate maker that market share trends are improving. " Goldman Sachs reiterates Nvidia & Micron as buys Goldman said it's standing by shares of Nvidia and Micron. Bank of America upgrades ZoomInfo to buy from neutral Bank of America said the software company is a "self-help" story. Bernstein reiterates Qualcomm as outperform Bernstein said it's bullish heading into Qualcomm earnings later this week.

Persons: Wells, Jefferies, it's, Evercore, Bernstein, Hershey, Goldman Sachs, Goldman, Raymond James, Sherwin, Williams, Morgan Stanley, William Blair, Morgan Stanley downgrades Brown, Forman Organizations: UBS, Amazon, Amazon Web Services, Citi, Air, Deutsche Bank, TFI, Deutsche, JPMorgan, Warner Brothers Discovery, Microsoft, Meta, YouTube, Nvidia, Micron, MU, Netflix, Barclays, Apple, Colgate, Palmolive, " Bank of America, of America, Beam Therapeutics, Bank of America, Builders, Devices, AMD, Qualcomm Locations: Norfolk Southern, Atlanta

☆ Beam Therapeutics to cut 20% of workforce as part of restructuring plan
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +2 min

Companies Beam Therapeutics Inc FollowOct 19 (Reuters) - Beam Therapeutics (BEAM.O) said on Thursday it will focus on developing its experimental sickle cell disease treatments and reduce about 20% of its current workforce, or 100 employees, as part of a restructuring plan. The gene-editing specialist expects to incur one-time expenses of about $6.6 million related to the workforce reduction, which it plans to complete in the fourth quarter. Its experimental sickle cell disease treatments include early-stage candidate BEAM-101, which activates fetal hemoglobin, the dominant form of hemoglobin present in the fetus during gestation. Beam will pause the development of its hepatitis B virus candidate, currently being evaluated in lab studies, and explore partnership opportunities for it. Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Beam, David Liu, Feng Zhang, J Keith Joung, Bhanvi Satija, Christy Santhosh, Shilpi Majumdar Organizations: Beam Therapeutics, U.S . Food, Drug Administration, Thomson Locations: Cambridge , Massachusetts, Bengaluru

☆ Gay male couples face more challenges, higher costs to start a family
▼ + stars: | 2023-06-23 | by ( Courtney Reagan | ) www.cnbc.com time to read: +9 min

watch nowWhy gay male couples face higher costsAlon Rivel, left, with his family. Gay male couples typically face a more expensive journey, as surrogacy or adoption are their primary choices. Employer fertility benefits offer limited helpMore employers are starting to offer fertility benefits, often through a specialized fertility benefits manager like Kindbody, Carrot, Progyny or Maven. But while more companies are offering fertility benefits, many of these packages are limited when it comes to covering what's needed to build families with non-traditional methods. At Rivel's insistence, he asked his human resources department to look into including surrogacy benefits.

Persons: Alon Rivel, Alon Rivel Alon Rivel, Rivel, Betsy Campbell, Maven, Will Porteous, Doug, Walter ., Porteous, Progyny's, Pete Anevski, Tammy Sun, Taryn Branca, they'll, Anevski, it's, Resolve's Campbell, Hanna, Stephen Hanna, Bret Shuford, Maverick Organizations: International Foundation of Employee, Equality, Mercer, Maven, Beam Therapeutics, Child Welfare Locations: Arlington , Massachusetts, U.S, Wynnewood , Pennsylvania, West, Massachusetts

☆ Small caps are finally starting to join the rally in June. Here's how to play their comeback
▼ + stars: | 2023-06-08 | by ( Fred Imbert | ) www.cnbc.com time to read: +3 min

Small stocks are making big moves this month, which could signal good news is ahead for Wall Street. The Russell 2000 , which is made up of small-cap names, is higher by 7% in June. .RUT 1M mountain Russell 2000 in past month "Moreover, small-caps have traditionally served as a bellwether in terms of the broader economic landscape," Krosby added. On top of that, Wolfe Research strategist Rob Ginsberg warned that the Russell 2000 could run into some technical resistance after the recent rally. That said, there are ways investors can try to capitalize on the small-cap rally.

Persons: Russell, Quincy Krosby, Krosby, Wolfe, Rob Ginsberg, Ginsberg Organizations: Financial, of Labor Statistics, Wolfe Research, CNBC Pro, Energy, NOVA, Beam Therapeutics, Rocket Pharmaceuticals, Arrowhead Pharmaceuticals Locations: U.S

☆ Citi names its top biotech and pharma stock picks, giving one nearly 90% upside
▼ + stars: | 2023-05-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The healthcare sector outperformed in Europe, India and China last month, according to Citi, which named its top picks worldwide. It gave Amylyx a price target of $53, giving it upside of around 88% from current levels. It gave Beam a price target of $60, implying upside of around 67%. Other European picks from Citi include Swiss healthcare company Roche and British pharma and biotech firm AstraZeneca . Asia stocks In Asia, Citi named Japanese pharmaceutical company Daiichi Sankyo , South Korean biotech firm Samsung Biologics and China's Wuxi Biologics as top picks.

☆ CRISPR pioneer Feng Zhang plans to 'break open the barrier' facing gene editing after raising $193 million for his secretive new startup
▼ + stars: | 2023-02-16 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

Feng Zhang, Aera's founder and a CRISPR pioneer, spoke with Insider about his vision for the firm. Aera wants to "break open the barrier" of tech through methods like gene editing, Zhang said. The CRISPR pioneer Feng Zhang spoke with Insider about Aera Therapeutics, his Boston-based biotech. "The goal is to break open the barrier that's facing genetic medicine," Zhang told Insider in his first interview about the company. In starting another company, Zhang said he felt it was important to have a dedicated team focused on delivery.

☆ CRISPR pioneer Feng Zhang's secretive gene-editing startup has hired ex-Alnylam leaders as CEO and chair
▼ + stars: | 2023-02-07 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +4 min

The gene-editing startup Aera has hired biotech vets Akin Akinc as CEO and John Maraganore as chairman. CRISPR pioneer Feng Zhang's newest gene-editing venture has attracted two longtime leaders of the biotech giant Alnylam Pharmaceuticals, Insider has learned. Former Alnylam CEO John Maraganore is chairman of Aera. The SEND technology could allow gene-editing technology to treat more diseases. Based on Zhang's SEND research, Aera hopes to deliver gene-editing tools to more organs, ultimately expanding the number of diseases CRISPR can impact.

☆ These innovation stocks owned by Cathie Wood have double-digit upside, according to analysts
▼ + stars: | 2023-02-06 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Cathie Wood just scored her best month ever as her innovation stocks staged a big comeback, and some of her darlings still have double-digit upside ahead, according to Wall Street analysts. Wood's flagship Ark Innovation ETF (ARKK) jumped 27.8% in January alone, notching its strongest month since its inception in 2014 . We looked at companies with at least five analysts covering them, and these names below all have more than 10% upside in the next 12 months, according to FactSet. Wall Street analysts are most bullish on Ginkgo Bioworks , seeing the stock rally more than 140% in the next 12 months. Other biotech names in the space that analysts love are Verve Therapeutics , CRISPR Therapeutics , Beam Therapeutics and Twist Bioscience.

☆ Citi names its top biotech stock picks for 2023 — and gives one 73% upside
▼ + stars: | 2022-12-30 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Biotech has been a "stock-pickers market" — and it may have just what it takes to remain one in 2023, according to Citi. Under a bad recession scenario, Citi prefers names with large cash balances and which have already commercialized drugs, or which are on the verge of drug approvals. Some names that meet those criteria include Apellis Pharmaceuticals , Acadia Pharmaceuticals and Amylyx Pharmaceuticals , Citi said. Its pre-clinical pipeline could also "drive long-term value across a number of large market opportunities." "[Its] strong cash position makes BEAM attractive even in a hard-landing scenario," Citi said.

☆ BMO upgrades this gene-editing play, sees shares returning 65% next year
▼ + stars: | 2022-12-20 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

BMO Capital Markets sees a big year ahead for biotech company Beam Therapeutics . Analyst Kostas Biliouris upgraded shares to outperform from market perform, saying he expects updates next year on a key partnership will drive upside for the gene-editing technology company. Beam has a partnership with biotech company Verve Therapeutics , which is using Beam's base editing technology for its VERVE-101 program. "We believe these catalysts will have a direct readthrough on BEAM, each driving a ~10%+ upside (stock moves here)." Shares of Beam Therapeutics are down more than 49% in 2022, while Verve Therapeutics is off by about 51%.

☆ Stocks making the biggest moves in the premarket: General Mills, Steelcase, Lucid and more
▼ + stars: | 2022-12-20 | by ( Peter Schacknow | ) www.cnbc.com time to read: +2 min

Lucid (LCID) – Lucid rallied 5.% in premarket trading after the electric vehicle maker raised more than $1.5 billion in a series of stock sales. Rocket Lab (RKLB) – Rocket Lab fell 1.3% in premarket action after announcing a delay in its first rocket launch from the United States. Rocket Lab cited both poor weather conditions as well as regulatory delays stemming from the processing of documentation by NASA and the Federal Aviation Administration. As a result, Rocket Lab cut its revenue forecast for the fourth quarter. BMO expects positive announcements from Beam's partner Verve Therapeutics (VERV) to help drive the stock higher.

☆ How a gene-editing breakthrough from a Harvard lab saved the life of a girl with leukemia
▼ + stars: | 2022-12-19 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +6 min

A 13-year-old girl was the world's first patient to get a cell therapy called base editing in May. Base editing is a new gene-editing technology that could lead to cures for many diseases. Alyssa, 13, was the first-ever patient to receive a base-edited cell therapy after enrolling in a clinical trial in May. Base editing allows scientists to make ultraprecise changes to single letters of DNA in cells. Alyssa, a teenager in Leicester, England, received a base-edited cell therapy to treat her leukemia.

☆ Prime Medicine dipped 10% in its public debut. We dug through the biotech's 283-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
▼ + stars: | 2022-10-20 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

The gene-editing biotech Prime Medicine went public on Thursday. From a key patent to an uncertain timeline, here are five takeaways from Prime's filing. Its goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing, another version of next-generation gene editing, works like a word processor, "searching for the correct location and replacing or repairing a wide variety of target DNA," the filing said. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is Prime's largest shareholder.

☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.

☆ CRISPR pioneer Feng Zhang is building a secretive new startup to solve gene-editing's biggest problem — getting into more parts of the body
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +6 min

CRISPR pioneer Feng Zhang is building a new gene-editing startup, Insider has learned. CRISPR pioneer Feng Zhang is in the process of launching yet another ambitious gene-editing startup, backed by approximately $200 million from some of biotech's biggest investors, Insider has exclusively learned. Aera was incorporated in September 2021, shortly after Zhang's research was published in Science. Aera is at least the seventh startup Zhang has cofounded, joining a list that includes base-editing biotech Beam Therapeutics, CRISPR company Editas Medicine, and gene-editing startup Arbor Biotechnologies. While the ARC protein seems tailored for brain delivery, Zhang's suite of proteins could reach other organs, Shepherd said.

☆ Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech's 282-page filing to find 5 key takeaways about the company's plan to commercialize gene editing.
▼ + stars: | 2022-09-28 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

From an uncertain timeline to the clinic to a key patent, here are 5 takeaways from Prime's filing. The company's goal is to advance prime editing, a twist on CRISPR gene editing that could allow for a wider range of edits to DNA. Prime editing is another version of next-generation gene editing. Prime's filing comes in a difficult market for biotechs, but particularly for companies that have yet to start human testing. Jessica Rinaldi/The Boston Globe via Getty ImagesDavid Liu, a Harvard gene-editing scientist who co-invented base editing and prime editing, is currently Prime's largest shareholder.

Search resuls for: "Beam Therapeutics"

19 mentions found